Americans are taking GLP-1 drugs in record numbers

A new analysis from The Washington Post shows that Americans are using GLP-1 drugs at unprecedented rates. Monthly prescriptions for medications like Ozempic, Mounjaro, and Wegovy have climbed to nearly 30 million, with a significant portion of the increase coming from patients who are new to these treatments.

Key takeaways

• GLP-1 drug prescriptions in the U.S. have reached approximately 30 million per month, according to data from IQVIA analyzed by The Washington Post.
• Nearly half of the new prescriptions written in 2024 went to patients who had not previously taken a GLP-1 drug, signaling a widening patient base.
• Ozempic and Mounjaro together accounted for about half of all GLP-1 prescriptions in 2024.
• Many new users are younger and starting on lower doses, which may reflect use for weight loss rather than diabetes.
• Demand continues to outpace supply, with shortages of some brand-name and compounded versions still being reported.

Record prescription numbers

According to The Washington Post’s analysis of prescription data from IQVIA, the number of monthly GLP-1 prescriptions written in the United States has reached roughly 30 million. That represents a dramatic increase from just a few years ago, when these medications were used primarily by people with type 2 diabetes.

The analysis found that Ozempic and Mounjaro, both made by Novo Nordisk and Eli Lilly respectively, together made up about half of all GLP-1 prescriptions filled in 2024. Other popular drugs in this class include Wegovy, Zepbound, and Rybelsus.

Who is starting these drugs?

A notable finding from the report is that about 48 percent of new GLP-1 prescriptions issued in the first half of 2024 went to people who had never taken a drug in this class before. This suggests that the market is not merely shifting existing patients between different brand names but is actually bringing in a large wave of new users.

The Post’s analysis also indicated that a growing number of these new patients are younger and are starting on lower doses. This pattern is consistent with the drugs’ growing popularity for weight management, rather than strictly for diabetes. Wegovy and Zepbound, for instance, are specifically approved for chronic weight management in the U.S.

How GLP-1 drugs actually work

To understand why demand exploded, it helps to know what these drugs do inside the body. GLP-1 is a natural gut hormone released after you eat. It tells the pancreas to release insulin when blood sugar is high, slows how fast the stomach empties, and signals the brain that you are full. The medications are engineered versions of that hormone that last for days instead of minutes, so the fullness signal stays switched on. In practice, people feel hungry less often and satisfied sooner, which quietly lowers how much they eat without the constant hunger that wrecks most diets.

Not all of these drugs are identical. Semaglutide, sold as Ozempic for diabetes and Wegovy for weight, targets the single GLP-1 receptor. Tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight, hits two receptors at once, GLP-1 and a second gut hormone called GIP, which is part of why it tends to produce larger weight loss in head-to-head data. This distinction matters for anyone comparing brands, because the name on the pen changes both the expected result and the price.

What the weight-loss evidence actually shows

The prescription surge is not built on hype alone. In the STEP trials that led to Wegovy’s approval, adults with obesity lost on average roughly 15 percent of their body weight over about 68 weeks, far beyond what earlier weight-loss drugs delivered. In the SURMOUNT trials for tirzepatide, the highest dose pushed average loss toward 20 percent or more. Those are large, clinically meaningful numbers, and they explain why physicians and patients alike treat this class as a genuine break from the past.

The honest caveat is that trial averages are not promises. Some people respond dramatically, others lose far less, and results depend on staying on the drug, tolerating it, and pairing it with reasonable eating. The medication also does not choose where the weight comes from, which is the concern covered further down. Averages this good still contain a wide range of individual outcomes.

The benefits are starting to reach beyond the scale

Part of what is fueling the prescription boom is a run of research suggesting these drugs do more than shrink waistlines. In a large cardiovascular outcomes trial, semaglutide reduced the risk of major cardiovascular events such as heart attack and stroke in people with established heart disease and overweight or obesity, even those without diabetes. Researchers are also studying effects on sleep apnea, fatty liver disease, and kidney outcomes, with early results that have widened the medical case for use.

This is the deeper reason the class is being treated as a turning point rather than a fad. If a weight-loss drug also lowers hard cardiovascular risk, it starts to look less like a cosmetic option and more like a metabolic medicine. That reframing is exactly what is drawing in clinicians who were previously skeptical of prescribing anything for weight at all.

Why this new wave of users is different

The finding that nearly half of new prescriptions go to first-time users, many of them younger and starting on low doses, points to a real shift in who these drugs are for. A decade ago the typical patient had type 2 diabetes and a long history of failed interventions. Today a large share are people seeking weight management, often paying out of pocket and often accessing prescriptions through telehealth rather than a traditional clinic visit.

That change brings both promise and pitfalls. On one hand, treating excess weight earlier, before it hardens into diabetes or heart disease, could prevent a lot of downstream illness. On the other, a younger cash-paying market is exactly the audience the gray market targets, and starting a chronic-tendency condition on an unsupervised drug is how avoidable harm happens. The wider the door opens, the more the quality of the clinician behind the prescription matters.

Supply and demand challenges

Despite the surge in manufacturing capacity, the report notes that shortages continue to affect the availability of some GLP-1 products. The Food and Drug Administration has periodically listed certain doses of Ozempic, Mounjaro, and Wegovy as in short supply, which has driven some patients to seek compounded versions of the drugs.

The high demand has also led to an increase in off-label prescribing. While the FDA has approved these medications for specific indications, some doctors are prescribing them for patients whose conditions may not exactly match the approved criteria, particularly for weight loss.

The compounding boom, and why it carries more risk

Shortages of the brand-name pens opened the door to compounded semaglutide and tirzepatide, cheaper versions mixed by compounding pharmacies and sold heavily through online clinics. It is worth being precise about what these are. Compounded GLP-1 medications are legally prescribed through licensed clinicians and pharmacies, but they are not FDA-approved products, which means they have not gone through the same testing for purity, dose accuracy, and consistency as the brand drugs.

That gap matters most at the extremes of the market. Reputable telehealth clinics work with vetted pharmacies and supervise dosing. The gray market, meaning research-chemical websites and social-media sellers, is where the real danger sits: mislabeled concentration, dosing errors, and products that may not contain what the label claims. As the official shortages have eased, the rules around mass compounding have also been tightening, so anyone using a compounded version should be doing it through a real clinician, not a checkout page with no medical oversight.

Implications for patients and the healthcare system

The rising prescription numbers reflect a shift in how GLP-1 drugs are perceived and used. Originally developed for type 2 diabetes, they are now widely sought after for weight loss. This has created new discussions about insurance coverage, out-of-pocket costs, and long-term health outcomes.

Public health experts quoted in the original report caution that while these drugs can be effective, they are not a substitute for healthy lifestyle changes. Patients considering GLP-1 therapies should discuss the potential benefits and risks with their healthcare provider and be aware of the financial costs, which can exceed $1,000 per month without insurance.

How GLP-1s compare with older weight-loss options

The scale of the shift makes more sense against what came before. For decades the medical toolkit for obesity was thin: intensive diet and exercise programs that most people could not sustain, a handful of older drugs with modest results or unpleasant side effects, and bariatric surgery, which is effective but invasive and reserved for higher-risk patients. Lifestyle change alone typically produced single-digit percentage weight loss on average, and much of it crept back.

Against that backdrop, a weekly injection that delivers double-digit percentage loss for many people is a genuine leap, closer to surgical results than to anything in a pill before it. That does not make it right for everyone, and it does not erase the value of diet, sleep, and strength training, which still determine how much of the loss is fat and how durable it is. But it does explain why clinicians who once had little to offer are now writing these prescriptions in record numbers.

What to watch as use keeps growing

For anyone weighing this decision, a few practical points cut through the noise. First, treat the drug as one part of a plan and lock in protein and resistance training from day one, so the weight you lose is fat rather than muscle. Second, insist on a real clinician and baseline labs, both to catch contraindications and to track what is happening beneath the scale. Third, be honest with yourself that stopping usually means regain, so think of this as a long-term commitment rather than a quick fix.

At the system level, the open questions are cost and access. Insurance coverage for weight loss is inconsistent, out-of-pocket prices are high, and that gap is precisely what pushes people toward compounded and gray-market products. As more data arrives on long-term safety and on what happens when large numbers of people stay on these drugs for years, both the medical guidance and the coverage rules are likely to keep shifting. For now, the smartest move is the same one it has always been: measure first, use supervision, and build the habits that make any result last.

The side effects new users should expect

Because so many first-time users are starting these drugs, the side-effect picture deserves plain language. The most common issues are gastrointestinal: nausea, vomiting, diarrhea, and constipation, which is why doctors start low and increase the dose slowly. For most people these ease over a few weeks as the body adapts. Eating smaller, lower-fat meals and stopping when full, rather than pushing through, blunts the worst of it.

Less common but more serious concerns include pancreatitis and gallbladder problems, the latter partly because rapid weight loss itself raises gallstone risk. These drugs also carry a boxed warning against use in people with a personal or family history of medullary thyroid cancer or the MEN2 syndrome, based on animal studies. None of this means the drugs are unsafe when supervised, but it is the reason a real clinician and a baseline workup beat a no-questions-asked online order.

The muscle-loss problem almost no one mentions

Here is the detail that gets lost in the excitement. When you lose weight quickly on a GLP-1, a meaningful share of what comes off can be lean mass, not just fat. Muscle is the tissue that keeps your resting metabolism high, so losing it makes future weight harder to keep off and can leave people lighter but weaker. This is not a reason to avoid the drugs, it is a reason to use them deliberately: prioritize protein, around 0.7 to 1 gram per pound of goal body weight, and do resistance training two to three times a week while the weight comes off.

It is also the argument for measuring, not guessing. A rapid drop can pull down more than fat, and the markers that tell you whether your body is losing muscle, running into a thyroid or insulin issue, or developing a nutrient gap do not show up on a bathroom scale. Getting a full panel before you start and again a few months in turns a blind experiment into something you can actually steer.

How to start a GLP-1 safely, and what it costs

If you are one of the millions considering this route, the safe path is boring and it works. Start with a clinician who takes a history, checks for the contraindications above, orders baseline labs, and follows you as the dose climbs. Skip any site that will sell you a vial without a real medical review, because that is where the dosing accidents and counterfeit products live. Brand-name pens frequently run more than $1,000 a month without insurance, while supervised compounded programs are usually cheaper, though quality depends entirely on the clinic and pharmacy behind them.

Coverage remains the wild card. Many insurers pay for these drugs for type 2 diabetes but not for weight loss, which is why so many people end up paying cash or turning to compounded options. Whatever route you take, the medication is a tool inside a plan, not the whole plan. The people who keep the weight off are the ones who use the appetite quiet to build better eating and training habits while they have the window.

It also helps to set expectations for the first few months. Doses climb slowly on purpose, so early weeks are about tolerating the medication rather than chasing fast results, and the biggest losses tend to come once you reach a maintenance dose. Keep a simple record of weight, waist, and how you feel, and bring it to each check-in. That record, not a single scale reading, is what lets you and your clinician decide whether the plan is working or needs adjusting.

Frequently Asked Questions

What are GLP-1 drugs?

GLP-1 drugs, also known as glucagon-like peptide-1 receptor agonists, are a class of medications that help manage blood sugar levels and promote satiety. They are used to treat type 2 diabetes and, in some formulations, for chronic weight management. Popular brands include Ozempic, Mounjaro, Wegovy, and Zepbound.

Why are GLP-1 prescriptions rising so quickly?

The rapid increase is driven by growing awareness of their weight loss benefits, broader insurance coverage for weight management, and aggressive marketing by drug manufacturers. The Washington Post report indicates that nearly half of new prescriptions are going to first-time users, many of whom are seeking help with weight loss rather than diabetes control.

Are GLP-1 drugs safe for weight loss?

When used under medical supervision and as approved by the FDA, GLP-1 drugs are considered safe for weight loss. However, they can cause side effects such as nausea, vomiting, and diarrhea. Long-term studies are still ongoing, and experts recommend that patients use these medications as part of a comprehensive plan that includes diet and exercise.

How much weight can you expect to lose on a GLP-1?

In the major trials, average loss ran roughly 15 percent of body weight on semaglutide and around 20 percent on the highest dose of tirzepatide over more than a year. Individual results vary widely, and the loss depends on staying on the drug, tolerating the dose, and pairing it with sensible eating and activity. Trial averages describe a group, not a guarantee for any one person.

Do you regain the weight if you stop?

Often, yes. When people stop a GLP-1, appetite returns and studies have shown most regain a large share of the weight within about a year. That is because the drug manages a chronic condition rather than curing it, similar to blood-pressure medication. Building strong nutrition and strength-training habits while on the drug gives people the best chance of holding their results if they later come off.

Is compounded semaglutide the same as Ozempic or Wegovy?

No. Compounded semaglutide contains the same active molecule but is not an FDA-approved product, so it has not passed the same checks for purity and dose consistency. It is legal when prescribed by a licensed clinician through a licensed pharmacy, but quality varies by source, and gray-market versions bought without medical oversight carry real risks. If you use a compounded version, do it through a supervised clinic.

Should I get labs before starting a GLP-1?

Yes. Baseline labs help a clinician confirm the drug is appropriate, rule out contraindications, and give a starting point to track. Because rapid weight loss can cost muscle and shift metabolic markers, retesting a few months in helps you steer the process rather than fly blind. This is standard practice at any responsible telehealth program.

Where can I get a GLP-1 prescription safely?

Through a licensed clinician who reviews your history and labs, whether that is your primary-care doctor, an endocrinologist, or a reputable telehealth clinic that prescribes only after a real medical review. Avoid any seller that ships a vial with no clinician involved. The legitimate route costs a little more effort up front and is far safer than a checkout page promising the drug with no questions asked.

Are GLP-1 drugs only for people with a lot of weight to lose?

The weight-management approvals target people with obesity, or overweight plus a related health condition, rather than someone looking to drop a few vanity pounds. Using them outside those criteria is off-label and a decision for you and a clinician, weighing the side effects, cost, and the reality that stopping usually brings the weight back. They are powerful tools for the right person, not a casual shortcut.

Can you build muscle while on a GLP-1?

You can at least protect it, and that is the priority. In a calorie deficit it is hard to add much muscle, but resistance training two to three times a week plus adequate protein signals the body to hold onto the muscle it has while fat comes off. Skipping that step is why some people finish a course of the drug lighter but softer and with a slower metabolism.

Why are younger people starting these drugs now?

Awareness of the weight-loss results, easier telehealth access, and the arrival of lower-cost compounded versions have all pulled the average user younger. Many are starting on low doses for weight management rather than diabetes. The upside is treating weight earlier, before complications set in; the risk is that a younger, cash-paying market is the main target of unsupervised gray-market sellers.

Are the results permanent?

The weight loss lasts as long as the treatment and the habits behind it do. Because these drugs manage appetite rather than resetting it permanently, most people regain weight after stopping unless they have built durable nutrition and training routines. That is why clinicians frame them as long-term management of a chronic condition, not a one-time cure.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.